Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Jul 19th, 8:28 PM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 33.38 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sets Key Dates for 25% Preferred Stock Dividend
Nutriband (NASDAQ: NTRB) is reminding shareholders of its upcoming 25% preferred stock dividend. Shareholders of record as of July 25, 2025, will receive one preferred share for every four common shares held, with the dividend payable on August 5. Each preferred share will be convertible to one common share upon FDA approval of Nutriband’s AVERSA Fentanyl product. Unconverted preferred shares will be eligible for annual cash dividends from company profits at the discretion of the board.
Via Investor Brand Network · July 18, 2025
Individuals Who Develop Multiple Sclerosis Have More Doctor Visits Decades Before Their Diagnosis
A new study has found that individuals who are later diagnosed with multiple sclerosis (MS) tend to visit their doctor more, are admitted to hospitals more, and visit emergency rooms more frequently decades before they are eventually diagnosed with MS in comparison to those who don’t develop the condition . This often happens more than 20 years before an MS diagnosis is made.
Via Investor Brand Network · July 18, 2025
Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial
Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and serves as principal investigator for the confirmatory phase 3 FLASH2 trial, which recent data from the IIS indicates is delivering promising treatment success in early-stage cutaneous T-cell lymphoma (“CTCL”).
Via Investor Brand Network · July 18, 2025
The results of the 2025 American Consumer Awards in the ‘Automotive' category, organized by the American Consumer Right Association and managed by the American Consumer Assessment, have been announced for the New York region.
Via Get News · July 17, 2025
Study Provides Valuable Insights About Non-Smokers Who Develop Lung Cancer
Lung cancer, one of the most common types of cancer, has for a long time been known to largely develop among smokers. However, recent studies have established that around one quarter of people diagnosed with lung cancer has never smoked. This has baffled the scientific community as there was no clear explanation why such a significant proportion of lung cancer patients didn’t have a history of smoking.
Via Investor Brand Network · July 17, 2025
KFF Poll Reveals the Challenges Americans Face in Meeting Their Healthcare Costs
Recent polling by KFF has provided insights into the numerous challenges that Americans face in meeting their health care costs. The poll, conducted in May and whose findings were published in June this year, shows that one of the major worries that American families face is having unexpected medical bills to pay.
Via Investor Brand Network · July 15, 2025
Just over a year ago, Lucid Group entered 2024 as one of the electric vehicle industry’s most hyped stories. At the time, retail investors and EV enthusiasts alike were swept up in the belief that Lucid could become the next Tesla—a “millionaire-maker” stock that would transform early believers’
Via MarketMinute · July 15, 2025
The electric vehicle (EV) industry has never been short on excitement or high-stakes drama. From explosive growth stories to sudden downturns, few sectors on Wall Street ignite such passionate debate among investors. One of the companies at the heart of these debates is Lucid Group, Inc. (NASDAQ:LCID). Once touted
Via MarketMinute · July 15, 2025
Elon Musk’s EV giant has launched its first showroom in Mumbai and is expanding to New Delhi later this month, showcasing Model Y units imported from China.
Via Stocktwits · July 15, 2025
Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases
Spotlight Diagnostics, a startup based in Eindhoven, Netherlands, is developing a test kit that will enable personnel to rapidly test for infectious diseases without requiring lab facilities . The kit targets infectious diseases like malaria, Chlamydia, gonorrhea and others that take a huge toll on human life.
Via Investor Brand Network · July 11, 2025
Las Vegas, Nevada - July 10, 2025 - The retrofittable SmartTOP roof top module for the Ferrari Portofino M is now available. The latest development from Mods4cars makes everyday convertible use easier thanks to intelligent additional functions.“In addition to the Ferrari 360, F430 Spider, 458/488 Spider, California, F8, 296 GTS, and Portofino, we can now offer a convenient solution for the Ferrari Portofino M as well,” says PR spokesperson Sven Tornow.
Via Get News · July 10, 2025
Libertyville, IL () July 10, 2025 -- Auto Lab Libertyville expands into full-spectrum BMW maintenance, expertly addressing car owners’ issues and concerns.
Via Prodigy · July 10, 2025
New Study Suggests Concussions Could Lead to Higher Risks of Brain Cancer
A new study that has been published in JAMA Network has found that military veterans that sustained traumatic brain injuries (TBIs) had an elevated risk of developing cancerous brain tumors. Doctor Ian Stewart, who led this breakthrough study, explains that his team found that veterans that sustained moderate or severe TBIs had their likelihood of developing brain cancer increase by 90%.
Via Investor Brand Network · July 10, 2025
Luxury San Francisco-based limo company Limo SF VIP (888 888-0195) announces private chauffeured transportation services to and from major and smaller airports throughout the Bay Area.
Via Press Release Distribution Service · July 9, 2025
Brighton and Hove, Brighton () July 8, 2025 -- Bike Buyer UK makes it easier than ever to get a fast, fair, and free valuation for motorcycles with no pressure to sell.
Via Prodigy · July 8, 2025
Preclinical Study Finds a Way to Reverse Symptoms of Parkinson’s in Mice
University of Sydney researchers have, for the first time ever, targeted a malfunctioning protein in mice having symptoms akin to Parkinson’s symptoms and successfully improved motor function in the mice. This breakthrough finding could open the door to finding a similar way to treat Parkinson’s disease in humans.
Via Investor Brand Network · July 8, 2025
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49% stake in Cohen and Associates, LLC, a respected neuropsychiatry clinic based in western Florida ( https://ibn.fm/geIxF ).
Via Investor Brand Network · July 8, 2025
GMV Car Parts (+447367808606) has increased its workforce to strengthen service delivery for tyre pressure monitoring systems (TPMS) and essential automotive components across the UK.
Via Press Release Distribution Service · July 8, 2025
20 States File Lawsuit Against Trump Administration for Releasing Medicaid Data to DHS
Rob Bonta, the Attorney General of California, revealed on Tuesday that 20 states have filed a lawsuit challenging the federal government’s release of private Medicaid data to deportation personnel in June. The shared data affects millions of people enrolled in Medicaid.
Via Investor Brand Network · July 7, 2025
Mainz, Germany, July 5, 2025 -- As the global shift toward electric mobility accelerates, BTR New Material Group showcased at the 15th Advanced Automotive Battery Conference (AABC) Europe to present its cutting-edge materials roadmap for next-generation batteries.
Via Press Release Distribution Service · July 4, 2025
Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis
The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe pain, their high abuse potential has led to a growing demand for smarter, safer delivery systems. As policymakers, healthcare providers, and regulators seek solutions that balance medical necessity with public safety, innovative technologies are emerging that could reshape how these powerful drugs are administered.
Via Investor Brand Network · July 3, 2025
Study Discovers Genetic Mutation that Makes Solid Tumors Unresponsive to Immunotherapy
While studying why non-human primates aren’t as likely to suffer from certain cancers when compared to humans, UC Davis scientists discovered a genetic mutation that could explain this anomaly. Their findings were published in the Nature Communications journal. This discovery could open the door to the development of more powerful treatments for cancer.
Via Investor Brand Network · July 3, 2025
Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar
In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development ( https://ibn.fm/dz7eO ). The event offered an in-depth look at Soligenix’s ongoing confirmatory phase 3 trial for cutaneous T-cell lymphoma (“CTCL”), a rare non-Hodgkin’s lymphoma, and discussed promising data emerging from an investigator-initiated study conducted at the University of Pennsylvania. Soligenix, a late-stage biopharmaceutical company, is dedicated to developing and commercializing treatments for rare diseases and unmet medical needs, and HyBryte(TM) represents the company’s lead asset aimed at transforming the treatment landscape for CTCL.
Via Investor Brand Network · July 2, 2025
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Announces $20 Million Preferred Stock and Warrant Offering
Oragenics (NYSE American: OGEN) a developer of intranasal pharmaceuticals for neurological disorders, has entered into a placement agency agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, priced at $25.00 per unit. Each Warrant allows purchase of an additional Preferred share at $25.00, with Preferred shares convertible into common stock at $2.50. Gross proceeds could total $20 million, which will support ONP-2 concussion trials, R&D, repayment of a $3 million bridge note, and general corporate needs. Dawson James Securities, Inc. is acting as sole placement agent, with closing expected on or about July 2, 2025.
Via Investor Brand Network · July 1, 2025